Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer

This study has been completed.
Sponsor:
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00563420
First received: November 21, 2007
Last updated: October 22, 2013
Last verified: October 2013

November 21, 2007
October 22, 2013
November 2002
Not Provided
Number of early stage lung cancer/precancerous lesion detected [ Time Frame: Two years ]
Same as current
Complete list of historical versions of study NCT00563420 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer
Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer

Lung cancer is the commonest malignant disease with a 5-year survival of 14%. In Hong Kong, it accounts for about 30% of all cancer death. The poor prognosis of lung cancer is due largely to the late clinical presentation of the disease. In order to improve the prognosis of lung cancer, an obvious approach is to develop sensitive methods for detecting lung cancer at much earlier stages when treatment is more likely to be curative.

However, the best way for identifying early lung cancer is still need to be determined. We hypothesis that by examining specimens that contain shed bronchial epithelial cells i.e. sputum, lung cancer can be sampled in its earliest possible phase. And by using autofluorescence bronchoscopy, a system specifically designed to detect early lung cancer/pre-invasive lesions, to identify the source of abnormal cells, we may able to detect eraly lung cancer and followed by curative treatment to improve the prognosis of this disease.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Primary Purpose: Diagnostic
Lung Neoplasms
Procedure: Bronchoscopy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
400
June 2007
Not Provided

Inclusion Criteria:

  • Current or ex-smokers who have smoked at least 20-pack-years (e.g. 1 pack per day for 20 years or more)
  • Informed consent

Exclusion Criteria:

  • Known malignant disease
  • Unstable major medical disease
  • Bleeding disorder
  • Unwilling to have a bronchoscopy
  • Women currently pregnant or nursing
  • Known reaction to xylocaine, a local anaesthesia agent used for bronchoscopy
Both
40 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00563420
EC 1621-01, HARECCTR0500035
Not Provided
Not Provided
Hospital Authority, Hong Kong
Not Provided
Principal Investigator: Bing Lam, Dr Department of Medicine, Queen Mary Hospital/ The University of Hong Kong
Hospital Authority, Hong Kong
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP